Condition
Relapsed Ewing Sarcoma
Total Trials
5
Recruiting
1
Active
2
Completed
2
Success Rate
66.7%-20% vs avg
Key Insights
Highlights
Success Rate
67% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 59/100
Termination Rate
20.0%
1 terminated out of 5 trials
Success Rate
66.7%
-19.8% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
50%
1 of 2 completed with results
Key Signals
1 with results67% success
Data Visualizations
Phase Distribution
5Total
P 1 (4)
P 2 (1)
Trial Status
Completed2
Active Not Recruiting1
Recruiting1
Terminated1
Trial Success Rate
66.7%
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (5)
Showing 5 of 5 trials
NCT05734066Phase 1Recruiting
Study of Lurbinectedin Monotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Ewing Sarcoma
NCT03514407Phase 1TerminatedPrimary
A Study of INCB059872 in Relapsed or Refractory Ewing Sarcoma
NCT03635632Phase 1Active Not Recruiting
C7R-GD2.CART Cells for Patients With Relapsed or Refractory Neuroblastoma and Other GD2 Positive Cancers (GAIL-N)
NCT04661852Phase 1CompletedPrimary
Cabozantinib With Topotecan-Cyclophosphamide
NCT02546544Phase 2CompletedPrimary
Eurosarc Trial of Linsitinib in Advanced Ewing Sarcoma
Showing all 5 trials